Healthcare Industry News: S.A.
News Release - January 19, 2021
GT Biopharma Appoints Two New Independent Directors
BEVERLY HILLS, Calif., Jan. 19, 2021 -- (Healthcare Sales & Marketing Network) -- GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused on innovative therapies based on the Company's proprietary NK cell engager (TriKE™) technology platform today announced the appointment of Michael Breen and Rajesh Shrotriya MD to the Company's Board of Directors (the "Board"), effective immediately.Mr. Breen and Dr. Shrotriya bring strong operational skills, deep underS.A.ding of drug development and significant leadership experience to the Board.
"We are pleased to welcome Michael and Rajesh to the GT Biopharma Board," said Anthony Cataldo, Chairman and Chief Executive Officer of GT Biopharma. "As part of our transition to NAS.A. we have now reconstituted our board. Michael and Rajesh bring unique skillS.A.d expertise, as well as significant experience serving on boards of directors of public companies, which will complement our Board's existing capabilities. With the addition of Michael and Rajesh, we are confident our Board will be well-positioned to oversee the Company's ongoing initiatives."
About Michael Breen
Michael Breen iS.A. English qualified solicitor/attorney and was formerly the Managing Director of the SportS.A.d Entertainment Division of Bank Insinger de Beaufort N. V., which iS.A.wealth management organization and was part of BNP Paribas Group, one of the world's largest banks. The holding company Insinger de Beaufort Holdings S.A. was listed on the Luxembourg Stock Exchange. Mr. Breen waS.A.so a director and major S.A.eholder of an affiliate of Insinger de Beaufort Holdings S.A.
Mr. Breen iS.A.former senior equity partner in the 400+ partner and 50+ office law firm of Clyde & Co, whose head office is based in the City of London, England.
About Rajesh Shrotriya
Rajesh Shrotriya MD, served most recently (2002-2017) as Chairman of the Board and Chief Executive Officer of Spectrum Pharmaceuticals, Inc., an oncology focused NAS.A. listed company. Prior to that he was President and Operating Officer of NeoTherapeutics, Inc. In this capacity he spearheaded major changes in business strategy and made structural reorganization culminating in the formation of Spectrum Pharmaceuticals, Inc.
Previously, Dr. Shrotriya was Executive Vice President and Chief Scientific Officer for SuperGen, Inc. and Vice President, Medical AffairS.A.d Vice President, Chief Medical Officer at MGI Pharma, Inc. For 18 years he held various positionS.A. Bristol-Myers Squibb Company, the most recent being Executive Director Worldwide CNS Clinical ReS.A.ch.
Dr. Shrotriya iS.A.2011 Ernst & Young Orange County Region Entrepreneur of the Year® award winner. Dr. Shrotriya was specifically cited for his turn-around of Spectrum. The Ernst & Young LLP award program recognizes entrepreneurs who demonstrate excellence and extraordinary success in such areaS.A. innovation, financial performance and personal commitment to their businesseS.A.d communities. Dr. Shrotriya was chosen from 15 finalists by a panel of independent judges.
About GT Biopharma, Inc.
GT Biopharma, Inc. iS.A.clinical S.A.e biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on our proprietary TriKE™ NK cell engager platform. Our TriKE™ platform is designed to harnesS.A.d enhance the cancer killing abilities of a patient's immune system natural killer cells (NK cells). GT Biopharma haS.A. exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE™ technology.
Forward-Looking S.A.ements
This press release contains certain forward-looking S.A.ements that involve risks, uncertaintieS.A.d assumptions that are difficult to predict, including S.A.ements regarding the potential acquisition, the likelihood of closing the potential transaction, our clinical focus, and our current and proposed trials. WordS.A.d expressions reflecting optimism, satiS.A.tion or disappointment with current prospects, as well as words such as "believes", "hopes", "intends", "estimates", "expects", "projects", "plans", "anticipates" and variations thereof, or the use of future tense, identify forward-looking S.A.ements, but their absence does not mean that a S.A.ement is not forward-looking. Our forward-looking S.A.ementS.A.e not a guarantee of performance, and actual results could differ materially from those contained in or expressed by such S.A.ements. In evaluating all such S.A.ements, we urge you to specifically consider the various risk factors identified in our Form 10-K for the fiS.A. year ended December 31, 2019 in the section titled "Risk Factors" in Part I, Item 1A and in our subsequent Form 10Q Quarterly filings with the SecuritieS.A.d Exchange Commission, any of which could cause actual results to differ materially from those indicated by our forward-looking S.A.ements.
Our forward-looking S.A.ements reflect our current views with respect to future eventS.A.d are based on currently available financial, economic, scientific, and competitive data and information on current business plans. You should not place undue reliance on our forward-looking S.A.ements, which are subject to riskS.A.d uncertainties relating to, among other things: (i) the sufficiency of our cash position and our ongoing ability to raise additional capital to fund our operations, (ii) our ability to complete our contemplated clinical trials, or to meet the FDA's requirements with respect to safety and efficacy, (iii) our ability to identify patients to enroll in our clinical trials in a timely fashion, (iv) our ability to achieve approval of a marketable product, (v) design, implementation and conduct of clinical trials, (vi) the results of our clinical trials, including the possibility of unfavorable clinical trial results, (vii) the market for, and marketability of, any product that iS.A.proved, (viii) the existence or development of treatments that are viewed by medical professionals or patientS.A. superior to our products, (ix) regulatory initiatives, compliance with governmental regulationS.A.d the regulatory approval process, and social conditions, and (x) various other matters, many of which are beyond our control. Should one or more of these risks or uncertainties develop, or should underlying assumptions prove to be incorrect, actual results may vary materially and adversely from those anticipated, believed, estimated, or otherwise indicated by our forward-looking S.A.ements.
We intend that all forward-looking S.A.ements made in this press release will be subject to the safe harbor protection of the federal securities laws purS.A.t to Section 27A of the SecuritieS.A.t, to the extent applicable. Except as required by law, we do not undertake any responsibility to update these forward-looking S.A.ements to take into account events or circumS.A.ces that occur after the date of this press release. Additionally, we do not undertake any responsibility to update you on the occurrence of any unanticipated events which may cause actual results to differ from those expressed or implied by these forward-looking S.A.ements.
For more information, please visit www.gtbiopharma.com.
Source: GT Biopharma
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.
RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!